Showing 1 - 5 results of 5 for search 'Elizabeth L Alexander', query time: 0.03s Refine Results
  1. 1
    Intermediate-type vancomycin resistance (VISA) in genetically-distinct Staphylococcus aureus isolates is linked to specific, reversible metabolic alterations.

    Intermediate-type vancomycin resistance (VISA) in genetically-distinct Staphylococcus aureus isolates is linked to specific, reversible metabolic alterations. by Elizabeth L Alexander, Susana Gardete, Haim Y Bar, Martin T Wells, Alexander Tomasz, Kyu Y Rhee

    Published 2014-01-01
    Get full text
    Article
  2. 2
    Extended spectrum beta-lactamase-producing Enterobacteriaceae in international travelers and non-travelers in New York City.

    Extended spectrum beta-lactamase-producing Enterobacteriaceae in international travelers and non-travelers in New York City. by Scott A Weisenberg, Jose R Mediavilla, Liang Chen, Elizabeth L Alexander, Kyu Y Rhee, Barry N Kreiswirth, Stephen G Jenkins

    Published 2012-01-01
    Get full text
    Article
  3. 3
    Endemic Acinetobacter baumannii in a New York hospital.

    Endemic Acinetobacter baumannii in a New York hospital. by Scott A Weisenberg, Audrey N Schuetz, Elizabeth L Alexander, Brain Eiss, Maryam Behta, Lisa Saiman, Davise H Larone, Stephen G Jenkins, Kyu Y Rhee

    Published 2011-01-01
    Get full text
    Article
  4. 4
    Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19

    Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19 by Jennifer E. Sager, Asma El‐Zailik, Julie Passarell, Stefan Roepcke, Xiaobin Li, Melissa Aldinger, Ahmed Nader, Andrew Skingsley, Elizabeth L. Alexander, Wendy W. Yeh, Erik Mogalian, Chad Garner, Amanda Peppercorn, Adrienne E. Shapiro, Maribel Reyes

    Published 2023-06-01
    Get full text
    Article
  5. 5
    Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

    Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial... by Richard G. Wunderink, Evangelos J. Giamarellos-Bourboulis, Galia Rahav, Amy J. Mathers, Matteo Bassetti, Jose Vazquez, Oliver A. Cornely, Joseph Solomkin, Tanaya Bhowmick, Jihad Bishara, George L. Daikos, Tim Felton, Maria Jose Lopez Furst, Eun Jeong Kwak, Francesco Menichetti, Ilana Oren, Elizabeth L. Alexander, David Griffith, Olga Lomovskaya, Jeffery Loutit, Shu Zhang, Michael N. Dudley, Keith S. Kaye

    Published 2018-10-01
    Get full text
    Article

Search Tools: